

Claudio Adile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2712813/publications.pdf>

Version: 2024-02-01

46
papers

1,144
citations

361045

20
h-index

414034

32
g-index

46
all docs

46
docs citations

46
times ranked

986
citing authors

#	ARTICLE	IF	CITATIONS
1	Methadone as First-line Opioid for the Management of Cancer Pain. <i>Oncologist</i> , 2022, 27, 323-327.	1.9	11
2	Dual opioid therapy in a cancer patient with myasthenia gravis who developed respiratory depression from codeine. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2020-002745.	0.8	1
3	The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain. <i>Cancers</i> , 2021, 13, 1058.	1.7	8
4	Personalized goal for insomnia and clinical response in advanced cancer patients. <i>Supportive Care in Cancer</i> , 2020, 28, 1089-1096.	1.0	3
5	Association between alcoholism and symptom expression, patient symptom goals, and clinical response in advanced cancer patients. <i>Supportive Care in Cancer</i> , 2020, 28, 3361-3369.	1.0	2
6	Episodic Breathlessness with and without Background Dyspnea in Advanced Cancer Patients Admitted to an Acute Supportive Care Unit. <i>Cancers</i> , 2020, 12, 2102.	1.7	4
7	Personalized Pain Goals and Responses in Advanced Cancer Patients. <i>Pain Medicine</i> , 2019, 21, e215-e221.	0.9	3
8	Symptom Expression in Patients with Advanced Cancer Admitted to an Acute Supportive/Palliative Care Unit With and Without Delirium. <i>Oncologist</i> , 2019, 24, e358-e364.	1.9	6
9	Breakthrough Cancer Pain in Patients With Abdominal Visceral Cancer Pain. <i>Journal of Pain and Symptom Management</i> , 2019, 57, 966-970.	0.6	6
10	Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS&EMS study. <i>European Journal of Pain</i> , 2019, 23, 719-726.	1.4	17
11	Characteristics and care pathways of advanced cancer patients in a palliative-supportive care unit and an oncological ward. <i>Supportive Care in Cancer</i> , 2018, 26, 1961-1966.	1.0	6
12	Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients. <i>Cancers</i> , 2018, 10, 175.	1.7	44
13	Characteristics of advanced cancer patients who were readmitted to an acute palliative/supportive care unit. <i>Supportive Care in Cancer</i> , 2017, 25, 1947-1952.	1.0	12
14	Characteristics of patients with an unplanned admission to an acute palliative care unit. <i>Internal and Emergency Medicine</i> , 2017, 12, 587-592.	1.0	10
15	The effects of alcoholism and smoking on advanced cancer patients admitted to an acute supportive/palliative care unit. <i>Supportive Care in Cancer</i> , 2017, 25, 2147-2153.	1.0	7
16	Sleep disturbances in advanced cancer patients admitted to a supportive/palliative care unit. <i>Supportive Care in Cancer</i> , 2017, 25, 1301-1306.	1.0	40
17	The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids. <i>Supportive Care in Cancer</i> , 2017, 25, 645-649.	1.0	10
18	Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 27-34.	0.6	19

#	ARTICLE	IF	CITATIONS
19	Epidemiology and Characteristics of Episodic Breathlessness in Advanced Cancer Patients: An Observational Study. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 17-24.	0.6	33
20	The Palliative-Supportive Care Unit in a Comprehensive Cancer Center as Crossroad for Patients's Oncological Pathway. <i>PLoS ONE</i> , 2016, 11, e0157300.	1.1	36
21	Pain Intensity as Prognostic Factor in Cancer Pain Management. <i>Pain Practice</i> , 2015, 15, E1-8.	0.9	19
22	Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. <i>Supportive Care in Cancer</i> , 2015, 23, 1349-1354.	1.0	22
23	The Frequency of Alcoholism in Patients With Advanced Cancer Admitted to an Acute Palliative Care Unit and a Home Care Program. <i>Journal of Pain and Symptom Management</i> , 2015, 49, 254-257.	0.6	12
24	Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. <i>Supportive Care in Cancer</i> , 2015, 23, 3249-3255.	1.0	103
25	Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study. <i>Journal of Pain and Symptom Management</i> , 2015, 50, 579-586.	0.6	40
26	Sleep Disturbances in Patients With Advanced Cancer in Different Palliative Care Settings. <i>Journal of Pain and Symptom Management</i> , 2015, 50, 786-792.	0.6	69
27	Breakthrough Pain in Patients With Abdominal Cancer Pain. <i>Clinical Journal of Pain</i> , 2014, 30, 510-514.	0.8	18
28	Intranasal Fentanyl Versus Fentanyl Pectin Nasal Spray for the Management of Breakthrough Cancer Pain in Doses Proportional to Basal Opioid Regimen. <i>Journal of Pain</i> , 2014, 15, 602-607.	0.7	34
29	Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. <i>Current Medical Research and Opinion</i> , 2014, 30, 2063-2068.	0.9	17
30	Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies. <i>Current Medical Research and Opinion</i> , 2013, 29, 667-671.	0.9	31
31	Orphan symptoms in advanced cancer patients followed at home. <i>Supportive Care in Cancer</i> , 2013, 21, 3525-3528.	1.0	17
32	Changes of QTc interval after opioid switching to oral methadone. <i>Supportive Care in Cancer</i> , 2013, 21, 3421-3424.	1.0	12
33	Prognostic Factors of Survival in Patients With Advanced Cancer Admitted to Home Care. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 56-62.	0.6	39
34	Opioid Switching in Patients With Advanced Cancer Followed at Home. A Retrospective Analysis. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 298-304.	0.6	20
35	Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. <i>Current Medical Research and Opinion</i> , 2013, 29, 93-97.	0.9	39
36	Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. <i>Current Medical Research and Opinion</i> , 2013, 29, 661-666.	0.9	42

#	ARTICLE	IF	CITATIONS
37	Tapentadol in cancer pain management: a prospective open-label study. <i>Current Medical Research and Opinion</i> , 2012, 28, 1775-1779.	0.9	57
38	Emergencies in Patients With Advanced Cancer Followed at Home. <i>Journal of Pain and Symptom Management</i> , 2012, 44, 295-300.	0.6	39
39	Switching From Methadone to Tapentadol for Cancer Pain. <i>Journal of Pain and Symptom Management</i> , 2012, 44, e3-e5.	0.6	3
40	Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. <i>Current Medical Research and Opinion</i> , 2012, 28, 963-968.	0.9	52
41	Palliative Sedation in Advanced Cancer Patients Followed at Home: A Retrospective Analysis. <i>Journal of Pain and Symptom Management</i> , 2012, 43, 1126-1130.	0.6	33
42	Switching from oxycodone to methadone in advanced cancer patients. <i>Supportive Care in Cancer</i> , 2012, 20, 191-194.	1.0	16
43	Fentanyl Buccal Tablets for Breakthrough Pain in Highly Tolerant Cancer Patients: Preliminary Data on the Proportionality Between Breakthrough Pain Dose and Background Dose. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 464-469.	0.6	38
44	How Do Cancer Patients Receiving Palliative Care at Home Die? A Descriptive Study. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 702-709.	0.6	37
45	High doses of oxycodoneâ€“naloxone combination may provide poor analgesia. <i>Supportive Care in Cancer</i> , 2011, 19, 1471-1472.	1.0	36
46	Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. <i>Current Medical Research and Opinion</i> , 2010, 26, 2765-2768.	0.9	21